论文部分内容阅读
异基因骨髓移植(Allo-BMT)相关的免疫性抗白血病反应的存在已被确认。然而在淋巴瘤中,移植物抗肿瘤效应尚未被证实。本文分析118例连续样本复发的何杰金病(HD)与进展期非何杰金淋巴瘤(NHL)病人骨髓移植的结果。病人年龄均小于60岁,骨髓穿刺与活检无淋巴瘤侵犯证据。38例年龄小于50岁、有HLA相合供髓者进行异基因骨髓移植,余80例则接受经净化的自身骨髗移植(ABMT)治疗。二组的中数年龄均为26岁。
The existence of allo-BMT-associated immune leukemia response has been confirmed. However, in lymphoma, the anti-tumor effect of the graft has not been confirmed. This article analyzes the results of a bone marrow transplant in 118 consecutive patients with Hodgkin’s disease (HD) and advanced non-Hodgkin’s lymphoma (NHL). Patients were less than 60 years of age, bone marrow biopsy with no evidence of invasion of lymphoma. Thirty-eight patients younger than 50 years old had HLA-matched donor marrow for allogeneic bone marrow transplantation, and the remaining 80 patients received purified autologous bone graft (ABMT). The median age of both groups is 26 years old.